
WATERS CORP /DE/
97
Recent developments highlight Waters Corporation's strategic acquisitions, product approvals, earnings performance, and technological advancements.
- Waters' BD OneFlow diagnostic test cleared FDA review with a U.S. launch planned for spring 2027 [N1].
- The company expanded its proteomics business through the acquisition of MOBILion Systems [N2].
- Waters reported Q3 2026 earnings and revenues above prior guidance and raised its 2026 guidance [N6].
- The company started AI-powered peak integration technology to enhance analytical capabilities [N3].
- Waters expanded access to FDA-approved HPV screening tests through partnerships [N3].
Waters Corporation is a company specializing in analytical instruments and related services, with operations spanning biosciences, diagnostics, and analytical sciences. The company reported detailed financial results for Q3 2026, showing revenues of $1.767 billion and net income of $81 million. Waters maintains solid liquidity with a current ratio of 1.89 and cash and equivalents of $593 million as of October 3, 2026. The company has actively expanded its proteomics business through the acquisition of MOBILion Systems and is advancing product innovation, including AI-powered technologies and new diagnostic tests cleared by the FDA. Waters operates multiple business segments including Waters Biosciences, Waters Advanced Diagnostics, and Waters Analytical and Materials Sciences.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Waters Corporation reported Q3 2026 revenue of $1.767 billion and net income of $81 million, with a current ratio of 1.89 and cash equivalents of $593 million as of October 3, 2026 [S2]. Recent business developments include the acquisition of MOBILion Systems to expand proteomics capabilities and FDA clearance of the BD OneFlow test with a U.S. launch planned for spring 2027 [N1][N2]. The company also advanced AI-powered peak integration technology and expanded access to FDA-approved HPV screening tests through partnerships [N3].
Waters Corporation demonstrates strong business execution through strategic acquisitions and product innovation, including FDA-cleared diagnostic tests and AI integration. Its diversified segments and expanding proteomics capabilities position it well within specialized analytical markets. The company's solid liquidity and positive earnings results reflect operational stability. Continued advancements and partnerships in diagnostics and biosciences could enhance its market penetration and technological leadership.
Risks for Waters Corporation include potential challenges in integrating acquisitions such as MOBILion Systems and successfully commercializing new products like BD OneFlow. Regulatory hurdles and competitive pressures in the analytical instruments and diagnostics markets may impact growth. Financial performance could be affected by market volatility or operational disruptions. Maintaining innovation pace and managing costs are critical to sustaining profitability and market position.
Waters Corporation's moat is supported by its diversified portfolio of analytical instruments and diagnostic products, including proprietary technologies such as BD OneFlow and AI-powered peak integration. Its expansion into proteomics through strategic acquisitions like MOBILion Systems enhances its technological capabilities and market reach. The company's established partnerships to expand access to FDA-approved diagnostic tests further strengthen its competitive position. Waters' solid financial position and ongoing innovation contribute to its ability to maintain market presence in specialized analytical and diagnostic fields.
• Acquisition Integration Risk: Challenges in integrating MOBILion Systems could affect operational efficiency and strategic objectives.
• Regulatory and Market Risks: FDA approvals and regulatory compliance are critical; delays or issues could impact product launches and revenues.
• Competitive Pressure: The analytical instruments and diagnostics markets are competitive, requiring continuous innovation and differentiation.
Business trends: Expansion in proteomics and diagnostics through acquisitions and FDA-cleared products; integration of AI technologies.
Execution milestones: Successful acquisition of MOBILion Systems; FDA clearance and planned launch of BD OneFlow; advancement of AI-powered peak integration.
Key risks: Integration challenges of acquisitions; regulatory compliance and approval risks; competitive pressures in analytical and diagnostic markets.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Waters Corporation operates in analytical instruments and related services, including biosciences and diagnostics segments.
- The company reported Q3 2026 revenue of $1.767 billion and net income of $81 million as of October 3, 2026, according to its 10-Q filing [S2].
- Basic earnings per share for Q3 2026 were $0.83 and diluted EPS was $0.82 [S2].
- Liquidity ratios as of October 3, 2026, include a current ratio of 1.89 and a cash ratio of 0.27, with cash and equivalents totaling $593 million [S2].
- Waters completed the acquisition of MOBILion Systems to expand its proteomics business [N2].
- The BD OneFlow product passed FDA review with a U.S. launch planned for spring 2027 [N1].
- The company has started AI-powered peak integration technology [N3].
- Waters has partnerships to expand access to FDA-approved HPV screening tests [N3].
- The company operates multiple segments including Waters Biosciences, Waters Advanced Diagnostics, and Waters Analytical and Materials Sciences [S1,S2].
Generated 2026-11-11
- S1 | 2026-02-23 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-11-10 | www.nasdaq.com | Waters' BD OneFlow Tests Clear FDA Review; U.S. Launch Set For Spring 2027 | https://www.nasdaq.com/articles/waters-bd-oneflow-tests-clear-fda-review-us-launch-set-spring-2027
- N2 | 2026-11-09 | www.nasdaq.com | Waters Expands Proteomics Reach With MOBILion Systems Acquisition | https://www.nasdaq.com/articles/waters-expands-proteomics-reach-mobilion-systems-acquisition
- N3 | 2026-11-04 | www.nasdaq.com | Waters Q3 Earnings Call Highlights | https://www.nasdaq.com/articles/waters-q3-earnings-call-highlights
- N4 | 2026-11-03 | www.nasdaq.com | Stocks Supported by Strength in Chipmakers | https://www.nasdaq.com/articles/stocks-supported-strength-chipmakers
- N5 | 2026-11-03 | www.nasdaq.com | Stocks Rebound as Crude Oil Prices Fall and Chipmakers Recover | https://www.nasdaq.com/articles/stocks-rebound-crude-oil-prices-fall-and-chipmakers-recover
- N6 | 2026-11-03 | www.nasdaq.com | Waters Q3 Earnings & Revenues Beat Estimates, 2026 Guidance Raised | https://www.nasdaq.com/articles/waters-q3-earnings-revenues-beat-estimates-2026-guidance-raised
- N7 | 2026-11-03 | www.nasdaq.com | Waters Corporation Reports Third Quarter 2026 Financial Results | https://www.nasdaq.com/articles/waters-corporation-reports-third-quarter-2026-financial-results
- N8 | 2026-11-03 | www.nasdaq.com | Waters (WAT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates | https://www.nasdaq.com/articles/waters-wat-q3-earnings-taking-look-key-metrics-versus-estimates
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


